Table1_Does sacubitril/valsartan work in children with heart failure?—a pilot study.pdf

BackgroundSacubitril/valsartan is an angiotensin receptor neprilysin antagonist (ARNI) approved for adult heart failure (HF). Its safety and efficacy in pediatric HF patients with cardiomyopathy or congenital heart disease are poorly understood. A pilot study was conducted to assess the clinical response, efficacy and safety of sacubitril/valsartan in this population at a tertiary care hospital in China.MethodsClinical parameters of patients who received sacubitril/valsartan from January 2019 to March 2023 were retrospectively collected and analyzed. Children over 1 month with a left ventricular ejection fraction (LVEF)

背景：沙库巴曲/缬沙坦为一种血管紧张素受体-脑啡肽酶抑制剂（ARNI），已被批准用于成人心力衰竭（HF）的治疗。然而，该药物在患有心肌病或先天性心脏病儿的儿童心力衰竭患者中的安全性和有效性尚缺乏充分认识。为此，我国某三级甲等医院开展了一项试点研究，旨在评估沙库巴曲/缬沙坦在此类患儿群体中的临床反应、疗效及安全性。方法：回顾性收集并分析了2019年1月至2023年3月期间接受沙库巴曲/缬沙坦治疗的患者临床参数。研究对象为超过1个月的儿童，其左心室射血分数（LVEF）